Bradley Merrill Thompson, a Member of the Firm in the Health Care and Life Sciences practice, in the firm’s Washington, DC, office, was quoted in Fierce Healthcare, in “9 Companies Will Play a Huge Role in Shaping the FDA’s Novel Approach to Digital Health,” by Evan Sweeney.
Following is an excerpt:
But the chance to be a part of that initial pilot program is “a brass ring worth competing for,” Bradley Merrill Thompson, a medical device attorney at Epstein Becker Green, said in an email to FierceHealthcare.
“Basically, FDA is saying, ‘We're going to have a program, we don't know what it will include, but come be part of it and helped design your own regulatory system,’” he said. “That's pretty enticing for any company that plans to be in this area long term.”
